Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alejandra Arriaga

Nurse Practitioner Greenacres, FL Nurse Practitioner

NPI 1952917684 CMS profile 10938065

6295 Lake Worth Rd Ste 30, Greenacres, FL 33463

Open in the dashboard

General payments

$10,922

646 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alejandra Arriaga of Greenacres, FL is reported in the CMS Open Payments database as having received $10,922 across 646 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2024 General $1,617 98
2023 General $5,149 293
2022 General $3,433 222
2021 General $708 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandra Arriaga
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Alejandra Arriaga were reported at $16. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Alejandra Arriaga Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $708 $135 $40–$426 $132
2022 $3,433 $152 $48–$470 $149
2023 $5,149 $166 $54–$529 $160
2024 $1,617 $173 $55–$556 $164
2025 $16 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $2,407 230 payments
  2. AbbVie, Inc. $2,080 87 payments
  3. Mallinckrodt Hospital Products Inc. $1,080 61 payments
  4. Novartis Pharmaceuticals Corporation $1,076 63 payments
  5. AstraZeneca Pharmaceuticals LP $956 46 payments
  6. Janssen Biotech, Inc. $665 24 payments
  7. UCB, Inc. $466 23 payments
  8. Lilly USA, LLC $455 25 payments
  9. Radius Health, Inc. $285 10 payments
  10. Horizon Therapeutics plc $252 15 payments
  11. Other $1,199 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,823 645 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $1,552 65 payments
  2. ACTHAR $1,080 61 payments
  3. Enbrel Inflammation $1,041 116 payments
  4. SAPHNELO $879 42 payments
  5. Enbrel Inflammation $810 83 payments
  6. Otezla $756 108 payments
  7. TREMFYA $617 22 payments
  8. COSENTYX Immunology $599 36 payments
  9. SKYRIZI $553 23 payments
  10. COSENTYX Dermatology $528 30 payments
  11. Other $4,135 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,464

Median for Nurse Practitioner: 389

Drug cost

$706,486

Median for Nurse Practitioner: $21,885

Branded share of claims

17.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 38 $243,605
Enbrel Sureclick Etanercept Brand 30 $240,674
Humira(Cf) Pen Adalimumab Brand 11 $76,538
Orencia Clickject Abatacept Brand 11 $61,075
Prolia Denosumab Brand 27 $46,502
Celecoxib Generic 122 $6,364
Hydroxychloroquine Sulfate Generic 170 $4,674
Diclofenac Sodium Generic 179 $3,894
Methotrexate Methotrexate Sodium Brand 227 $3,811
Leflunomide Generic 63 $2,771

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$46,473

Of which drugs: $33,447

Medicare patients

105

Average age 75

Services billed

2,173

92 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 50%
Diabetes 36%
Depression 33%
Ischemic heart disease 31%
Chronic kidney disease 29%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 28 1,680 $33,337

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $227
$227 38 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $212
$212 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $162
$162 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $146
$146 — —
Enbrel
  • Amgen Inc. $132
$132 30 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

646 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record